profit from every $100 of sales.
$0$100
Crinetics Pharmaceuticals
We have no price for Crinetics Pharmaceuticals since 2 September 2026. It may have been taken over, merged or renamed, so the figures below are from then.
$84.95+0.00% today
-4.4% since Oct 8, 25
1-year low $65.221-year high $112.86
Trading in the middle of its range for the past year.
The essentials
Four questions every investor asks, answered in one line each.
more sales each year, on average, 2022 to 2025.
0%20% a year
It has no yearly profit to compare the price with.
CheapExpensive
It holds more cash than debt.
No debt5 years
Money in, money out
What Crinetics Pharmaceuticals sold, what it kept, and what it did with the cash.
Sales went from $4.74 million in 2022 to $7.70 million in 2025, with -$465 million of profit last year.
SalesProfit
Crinetics Pharmaceuticals vs. similar companies
How it compares with the largest companies in its industry.
| Company | Profit from $100 of sales | Sales growth a year | Price per $1 of profit |
|---|---|---|---|
| Crinetics Pharmaceuticals | No profit yet | ||
 Vertex Pharmaceuticals | 35.1× · Expensive | ||
 Moderna | No profit yet | ||
 Regeneron Pharmaceuticals | 22.0× · Fair price | ||
 CSL | 22.1× · Fair price |
AI analysis
An AI analyst reads Crinetics Pharmaceuticals's last five years, its segments, earnings, insiders and peers, and writes the bull case, the bear case and what the price expects.
Run the AI analysisFull statementsIncome, balance sheet and cash flow, year by year
Income statement
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| 5 | 4 | 1 | 8 | |
| – | 4 | 1 | 7 | |
| -168 | -223 | -339 | -517 | |
| -167 | -222 | -336 | -513 | |
| -164 | -215 | -298 | -465 | |
| -3.15 | -3.69 | -3.69 | -4.95 | |
| – | 100.0% | 100.0% | 86.0% | |
| -3,544.1% | -5,547.2% | -32,613.5% | -6,714.8% | |
| -3,460.4% | -5,345.9% | -28,720.7% | -6,046.2% |
Balance sheet
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Total assets | 352 | 635 | 1,435 | 1,126 |
| Cash | 33 | 55 | 265 | 102 |
| Total debt | 3 | 52 | 52 | 49 |
| Total liabilities | 36 | 96 | 110 | 134 |
| 316 | 539 | 1,325 | 992 | |
| 52 | 58 | 81 | 94 | |
| -41.5% | -29.8% | -19.4% | -39.2% | |
| -51.8% | -39.8% | -22.5% | -46.9% |
Cash flow
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| -115 | -169 | -230 | -378 | |
| 2 | 5 | 4 | 6 | |
| -117 | -173 | -234 | -384 | |
| Dividends paid | – | – | – | – |
| – | 1 | 15 | 0 | |
| 28 | 41 | 69 | 91 |
Valuation
- –
- –
- –
- 3.0×
- 1,171.1×
- –
- –
- -4.3%
- -5.2%
- 0.0%
Profitability
- 86.0%
- -6,714.8%
- -6,046.2%
- -2,997.5%
- -40.8%
- -37.2%
- -44.0%
- -35.4%
- -41.0%
- 1,969.7%
Growth
- +17.6%
- –
- −67.0%
- –
- +25.1%
Financial health
- -0.1×
- 0.04
- 3.4%
- –
- 18.60
- 18.56
- 0.01
How it ranks in Healthcare
Each dot is where the company stands among every company over $300M in the sector. Further right is better.
Bottom 12%of 947
Top 33%of 866
Bottom 22%of 985
What analysts expect
- Average price target
- $86.60
- Range
- $67.00 – $105.00
These targets were collected on May 20, 2026 and our analyst feed has not updated since, so we no longer compare them with today's price.
Recent earnings
Our results feed has not updated since May 21, 2026. Results reported after that are not in this table yet.
| Date | EPS | Expected | Surprise |
|---|---|---|---|
| May 7, 2026 | -1.23 | -1.22 | −0.8% |
| Feb 26, 2026 | -1.29 | -1.37 | +5.8% |
| Nov 6, 2025 | -1.38 | -1.27 | −8.7% |
| Aug 7, 2025 | -1.23 | -1.13 | −8.8% |
| May 8, 2025 | -1.04 | -0.99 | −5.1% |
| Feb 27, 2025 | -0.88 | -0.92 | +4.3% |
| Nov 12, 2024 | -0.96 | -0.91 | −5.4% |
| Aug 8, 2024 | -0.94 | -0.86 | −9.3% |
News
Vertex outlines $13.15B-$13.25B 2026 revenue guidance while adding $40M-$50M from CrineticsSeeking Alpha · Nov 3, 2026Vertex wins Overweight at Morgan Stanley as coverage resumes after Crinetics buyoutSeeking Alpha · Sep 2, 2026Insider trades
Our insider feed has not updated since May 26, 2026. Trades filed after that are not listed yet.
No insider trades on file.
The seven classic investing rulebooks
1/7Passes 1 of 7. Each bar is how well the company fits that investor's published rules, from 0 to 100; 60 or more counts as a pass.
Warren Buffett
37No pass
Benjamin Graham
42No pass
Philip Fisher
57No pass
Peter Lynch
84Pass
Joel Greenblatt
2No pass
Charlie Munger
55No pass
Terry Smith
56No pass
Questions about Crinetics Pharmaceuticals
Is Crinetics Pharmaceuticals a good stock to buy?
A business with weak numbers that is not profitable yet. 1 of the 7 famous investors' published rulebooks we apply pass it. Whether it suits you depends on your goals and the price you pay; invest-like never tells anyone to buy or sell. The AI analysis lays out the case for and against. Read the Crinetics Pharmaceuticals AI analysis
What does Crinetics Pharmaceuticals do?
Crinetics Pharmaceuticals, Inc., a clinical stage pharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for rare endocrine diseases and endocrine-related tumors. It is in Biotechnology, based in San Diego, CA, United States, with 594 employees.
Does Crinetics Pharmaceuticals pay a dividend?
No. Crinetics Pharmaceuticals does not pay a dividend at the moment.
Is Crinetics Pharmaceuticals stock halal?
Yes. Crinetics Pharmaceuticals passes our halal screen: its business is permitted and its debt is 0.5% of its market value, under the 30% limit. How we check
Who are Crinetics Pharmaceuticals's competitors?
The largest listed companies in the same industry are Vertex Pharmaceuticals, Moderna, Regeneron Pharmaceuticals and CSL. The peers table on this page compares their profit, growth and price with Crinetics Pharmaceuticals's.
Prices: daily closes to Sep 2, 2026. Fundamentals: company reports via invest-like data.